Clinical Trial

A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)

Study acronym: ACH
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2016-03-25; most recent amendment 2026-03-12.
Status change: Enrolling by Invitation → Active, Not Recruiting 2018-01-16
Trial Details
NCT Number NCT02724228
Lead Sponsor BioMarin Pharmaceutical
Conditions Achondroplasia
Enrollment 30 participants
Start Date 2016-01-26
Primary Completion 2027-12 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-13